Payment overview · 2025
General Payments
$1,117.10
50 reported records · 14 companies
Healthcare provider profile · identity verified
Thomas Michael Browne, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · KNOX, IN · NPI 1548277288
Verified facts
What the public records show
CMS Open Payments records show Thomas Michael Browne, M.D. received $1,117.10 in general payments during 2025 across 50 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $203.46 | 18.2% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $190.31 | 17.0% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $155.19 | 13.9% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $153.84 | 13.8% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $100.82 | 9.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.26 | 5.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.33 | 5.3% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $48.94 | 4.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.02 | 3.5% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $32.07 | 2.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.66 | 1.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.37 | 1.6% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $17.31 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.52 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,117.10 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $190.31 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $167.67 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $155.19 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $133.06 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $116.33 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $97.27 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.26 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $66.26 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.84 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $48.94 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.12 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.91 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.02 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.98 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $32.07 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1985 | 171 |
| Sertraline Hcl | Sertraline Hcl | 1448 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1220 | 111 |
| Donepezil Hcl | Donepezil Hcl | 1117 | 48 |
| Furosemide | Furosemide | 1112 | 87 |
| Memantine Hcl | Memantine Hcl | 1029 | 39 |
| Lisinopril | Lisinopril | 948 | 104 |
| Gabapentin | Gabapentin | 912 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 899 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 832 | 94 |
| Eliquis | Apixaban | 604 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 598 | 60 |
| Carvedilol | Carvedilol | 586 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 579 | 58 |
| Potassium Chloride | Potassium Chloride | 571 | 60 |
| Losartan Potassium | Losartan Potassium | 546 | 66 |
| Metformin Hcl | Metformin Hcl | 544 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 481 | 46 |
| Tramadol Hcl | Tramadol Hcl | 418 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 399 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 387 | 71 |
| Trazodone Hcl | Trazodone Hcl | 348 | 41 |
| Mirtazapine | Mirtazapine | 329 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 325 | 44 |
| Levetiracetam | Levetiracetam | 316 | 15 |
| Ezetimibe | Ezetimibe | 273 | 36 |
| Omeprazole | Omeprazole | 261 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 257 | 27 |
| Buspirone Hcl | Buspirone Hcl | 254 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 230 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 227 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 225 | 22 |
| Lamotrigine | Lamotrigine | 219 | suppressed |
| Baclofen | Baclofen | 213 | suppressed |
| Famotidine | Famotidine | 201 | 31 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 194 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 188 | 13 |
| Spironolactone | Spironolactone | 160 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 152 | 14 |
| Propranolol Hcl | Propranolol Hcl | 152 | suppressed |
| Simvastatin | Simvastatin | 148 | 25 |
| Olanzapine | Olanzapine | 145 | 11 |
| Xarelto | Rivaroxaban | 137 | 16 |
| Alendronate Sodium | Alendronate Sodium | 129 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 124 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 115 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 111 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 108 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 11 |
| Risperidone | Risperidone | 105 | suppressed |
| Allopurinol | Allopurinol | 101 | 21 |
| Loperamide | Loperamide Hcl | 100 | 17 |
| Oxcarbazepine | Oxcarbazepine | 92 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 24 |
| Galantamine Hbr | Galantamine Hbr | 91 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 50 |
| Nitroglycerin Patch | Nitroglycerin | 86 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 39 |
| Amiodarone Hcl | Amiodarone Hcl | 84 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 83 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 83 | suppressed |
| Nifedipine Er | Nifedipine | 83 | suppressed |
| Alprazolam | Alprazolam | 79 | 29 |
| Glycopyrrolate | Glycopyrrolate | 79 | suppressed |
| Lorazepam | Lorazepam | 77 | 25 |
| Tradjenta | Linagliptin | 74 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 71 | suppressed |
| Torsemide | Torsemide | 70 | suppressed |
| Amantadine | Amantadine Hcl | 68 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 16 |
| Pregabalin | Pregabalin | 66 | 16 |
| Azithromycin | Azithromycin | 65 | 52 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 18 |
| Prednisone | Prednisone | 65 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 29 |
| Cephalexin | Cephalexin | 61 | 39 |
| Diltiazem 24hr Er | Diltiazem Hcl | 61 | suppressed |
| Myrbetriq | Mirabegron | 61 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 61 | 21 |
| Ozempic | Semaglutide | 60 | 17 |
| Aripiprazole | Aripiprazole | 58 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 57 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 57 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 17 |
| Meloxicam | Meloxicam | 54 | 32 |
| Metformin Hcl Er | Metformin Hcl | 54 | 22 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 53 | suppressed |
| Jardiance | Empagliflozin | 52 | 18 |
| Creon | Lipase/Protease/Amylase | 51 | suppressed |
| Topiramate | Topiramate | 47 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 46 | suppressed |
| Ibuprofen | Ibuprofen | 45 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 44 | 41 |
| Brilinta | Ticagrelor | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 26 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 41 | 39 |
| Metolazone | Metolazone | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 12 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Lubiprostone | Lubiprostone | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 32 |
| Lacosamide | Lacosamide | 37 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 37 | suppressed |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | 13 |
| Glimepiride | Glimepiride | 31 | 20 |
| Renvela | Sevelamer Carbonate | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 18 |
| Velphoro | Sucroferric Oxyhydroxide | 29 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Daptomycin | Daptomycin | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 20 |
| Lovastatin | Lovastatin | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 12 |
| Enulose | Lactulose | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 23 | suppressed |
| Xifaxan | Rifaximin | 23 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 11 |
| Nystatin | Nystatin | 22 | 13 |
| Admelog Solostar | Insulin Lispro | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Scopolamine | Scopolamine | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 19 | suppressed |
| Dalfampridine Er | Dalfampridine | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 13 |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Venlafaxine Besylate Er | Venlafaxine Besylate | 18 | suppressed |
| Levetiracetam Er | Levetiracetam | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 15 |
| Atenolol | Atenolol | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Meropenem | Meropenem | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Acetic Acid | Acetic Acid | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Paliperidone Er | Paliperidone | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Klayesta | Nystatin | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sotalol Af | Sotalol Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,117.10 · 50 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, CREON, CeQur Simplicity, Cologuard Collection Kit, FANAPT, FARXIGA, INGREZZA, JARDIANCE, KISUNLA, Kerendia, LINZESS, LOREEV XR, MOUNJARO, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error